Following differential diagnosis of drug-resistant CRC tumors, the potential of MRMI of EDB-FN for non-invasive assessment of therapeutic response was determined in DLD1-DR-bearing mice treated with MK2206-HCl, a pan-AKT inhibitor. This evidence concerns the gene AKT1 and colorectal carcinoma.